BioTuesdays

Category - Markets

Galmed Logo
Markets

Maxim cuts Galmed Pharma to hold; removes PT

Maxim Group downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “hold” from “buy” and removed its previous $14 price target after the company announced that top-line results from the ARRIVE trial...

February 14, 2018
Anavex
Markets

Maxim slashes PT for Anavex to $5 from $14

Maxim Group slashed its price target to Anavex Life Sciences (NASDAQ:AVXL) to $5 from $14, saying the company’s definitive proof-of-concept studies will take time and money. The stock closed at $2.54 on Feb. 13...

February 14, 2018
GlycoMimetics
Markets

Roth ups GlycoMimetics PT to $35

Roth Capital Partners raised its price target for GlycoMimetics (NASDAQ:GLYC) to $35 from $25 after the company agreed with the Dutch hematological oncology foundation, HOVON, to move towards a 140-patient study of GMI...

February 8, 2018
Conatus
Markets

Roth starts Conatus Pharma at buy; PT $20

Roth Capital Partners launched coverage of Conatus Pharmaceuticals (NASDAQ:CNAT) with a “buy” rating and $20 price target. The stock closed at $5.04 on Feb. 7. Conatus is a leader in the pan-caspase...

February 8, 2018
Aurinia Logo
Markets

RBC starts Aurinia Pharma at OP; PT $9

RBC Capital Markets initiated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with an “outperform, speculative risk” and price target of $9. The stock closed at $5.23 on Feb. 7. The company’s drug...

February 8, 2018
AxoGen
Markets

WB starts AxoGen at OP

William Blair launched coverage of AxoGen (NASDAQ:AXGN) with an “outperform” rating. The stock closed at $26.65 on Feb. 2. AxoGen is a global leader in the peripheral nerve repair and regeneration industry, and sells a...

February 5, 2018
Epizyme Logo
Markets

Roth starts Epizyme at buy; PT $24

Roth Capital Partners initiated coverage of Epizyme (NASDAQ:EPZM) with a “buy” rating and $24 price target. The stock closed at $16.15 on Jan. 31. Analyst Jotin Marango writes that during the past five years in the...

February 1, 2018
Zynerba Pharmaceuticals Logo
Markets

Ladenburg starts Zynerba Pharma at buy; PT $25.50

Ladenburg Thalmann initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and $25.50 price target. The stock closed at $12.07 on Jan. 26. Zynerba is developing two clinical-stage synthetic...

January 29, 2018
Protagonist Therapeutics
Markets

Stifel starts Protagonist Therapeutics at buy; PT $32

Stifel launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with a “buy” rating and a $32 target price. The stock closed at $19.23 on Jan. 26. Protagonist is leveraging its proprietary peptide technology platform...

January 29, 2018